{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:43Z","timestamp":1790409163977,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01160-1","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:03:10Z","timestamp":1729508590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of COVID-19 on outcomes with teclistamab in patients with relapsed\/refractory multiple myeloma in the phase 1\/2 MajesTEC-1 study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4505-6344","authenticated-orcid":false,"given":"Pragya","family":"Thaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Uhlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"N Raje","year":"2022","unstructured":"Raje N, Anaissie E, Kumar S, Lonial S, Martin T, Gertz M, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u2013161.","journal-title":"Lancet Haematol"},{"key":"1160_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.05.014","volume":"189","author":"S Rubinstein","year":"2023","unstructured":"Rubinstein S, Derman B. Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023;189:112926.","journal-title":"Eur J Cancer"},{"key":"1160_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00588-z","volume":"11","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina J, Zamanillo I, Lopez-Munoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198.","journal-title":"Blood Cancer J"},{"key":"1160_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.701","volume":"10","author":"H Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy H, Al-Gareeb A, Mohammed A, Alexiou A, Papadakis M, El-Saber Bathia G. The potential link between Covid-19 and multiple myeloma: a new saga. Immun Inflamm Dis. 2022;10:e701.","journal-title":"Immun Inflamm Dis"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood.2020008150","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari A, Samur K, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033\u201340.","journal-title":"Blood"},{"key":"1160_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Banejee S, Cervantes A, Garassino M, Garriso P, Girard N, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31:1320\u201335.","journal-title":"Ann Oncol"},{"key":"1160_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.htct.2020.05.001","volume":"42","author":"V Hungria","year":"2020","unstructured":"Hungria V, Garnica M, de Queiroz Cruso\u00e9 E, de Magalhaes Filho R, Martinez G, Bittencourt R, et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel \u2013 ABHH Monoclonal Gammopathies Committee. Hematol Transfus Cell Ther. 2020;42:200\u20135.","journal-title":"Hematol Transfus Cell Ther"},{"key":"1160_CR8","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus pandemic (COVID-19). 2020. https:\/\/ourworldindata.org\/coronavirus."},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos M-V, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886\u2013900.","journal-title":"Cancer"},{"key":"1160_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"J Tregoning","year":"2021","unstructured":"Tregoning J, Flight K, Higham S, Wang Z, Pierce B. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626\u201336.","journal-title":"Nat Rev Immunol"},{"key":"1160_CR11","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"key":"1160_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriel A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2022-162709","volume":"140","author":"D Cortes-Selva","year":"2022","unstructured":"Cortes-Selva D, Casneuf T, Vishwamitra D, Stein S, Perova T, Skerget S, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: correlative analyses from MajesTEC\u20111. Blood. 2022;140:241\u20133.","journal-title":"Blood"},{"key":"1160_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18909","volume":"203","author":"M Mohan","year":"2023","unstructured":"Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D\u2019Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023;203:736\u201346.","journal-title":"Br J Haematol"},{"key":"1160_CR15","doi-asserted-by":"publisher","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","volume":"8","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8:e934\u2013e946.","journal-title":"Lancet Haematol"},{"key":"1160_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","volume":"41","author":"P Moreau","year":"2024","unstructured":"Moreau P, Mateos M-V, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, et al. Comparative effectiveness of teclistamab versus real-world physician\u2019s choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:696\u2013715.","journal-title":"Adv Ther"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01160-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:04:31Z","timestamp":1729569871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01160-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01160-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NWCJvdD has served in a consulting\/advisory role for AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Servier, and Takeda; and has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis. NB has served in a consulting\/advisory role for Amgen, Celgene, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi, and Takeda; received honoraria from AbbVie, Amgen, Celgene, Genentech\/Roche, GSK, Janssen, Karyopharm Therapeutics, Sanofi, and Takeda; and has received research funding from Celgene, Janssen, and Pfizer. LJC has served in a consulting role for AbbVie, Amgen, BMS, Pfizer, and Sanofi; has received grants or contracts from AbbVie, Amgen, and BMS; and has received research funding from Janssen. M-VM reports honoraria from and membership on a board of directors and\/or advisory committee for Amgen, BMS\/Celgene, GSK, Janssen-Cilag, Pfizer, Sanofi, and Takeda; is a speakers bureau member for Janssen-Cilag; and is a board of directors and\/or advisory committee member for Oncopeptides. AKN has served on advisory boards and received honoraria from Adaptive Biotechnologies, Amgen, BeyondSpring, BMS, Cellectar Biosciences, GSK, Janssen, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Sanofi, Secura Bio, and Takeda; received grant\/research support (to university) from Aduro Biotech, Amgen, Arch Oncology, BMS, Cellectar Biosciences, Cellectis, Genentech, GSK, Janssen, Karyopharm Therapeutics, Kite Pharma, Merck, Pfizer, and Takeda; and received grant\/research support for investigator-initiated studies from Amgen, GSK, Janssen, Merck, and Takeda. AP has received honoraria or consultancy from AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi, and Takeda. ALG has served in a consulting or advisory role for Abbvie, Amgen, Bristol Myers Squibb\/Celgene, CDR-Life, GlaxoSmithKline, Gracell, Janssen Oncology, Novartis, Regeneron, and Smart Immune; received travel, accommodations, or expenses from Janssen; has a patent in the field of CAR-T cell therapy; and received research funding from Crispr Therapeutics, Janssen Oncology, Novartis, and Tmunity Therapeutics, Inc. PT, KQ, CU, KC, and MD are employees of Janssen. SZU has served in a consulting\/advisory role for AbbVie, Amgen, BMS\/Celgene, Celgene, Genentech, Genentech\/Roche, Gilead Sciences, GSK, Janssen Oncology, K36 Therapeutics, Karyopharm Therapeutics, and Takeda; and has received research funding from AbbVie, Amgen, Array BioPharma, BMS, Celgene, Gilead, GSK, Janssen Oncology, Merck, Pharmacyclics, Sanofi, Seagen, and SkylineDx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MajesTEC-1 study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each of the study sites (a full list of which has been published previously []). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"186"}}